BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36726488)

  • 21. Circulating CD4
    Zhao L; Li Z; Zeng X; Xia C; Xu L; Xu Q; Song Y; Liu C
    Int J Rheum Dis; 2021 Aug; 24(8):1032-1039. PubMed ID: 34227243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression of pSTAT3 and PD-L1 in extranodal NK/T cell lymphoma and its clinical significance].
    Zhang F; Luo DL; Chen Y; Yan JH; Luo LQ; Liu J; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2020 Oct; 49(10):999-1002. PubMed ID: 32992412
    [No Abstract]   [Full Text] [Related]  

  • 23. Increased percentage of PD-L1
    Jiang W; Li X; Wen M; Liu X; Wang K; Wang Q; Li Y; Zhou M; Liu M; Hu B; Zeng H
    Crit Care; 2020 Oct; 24(1):617. PubMed ID: 33076951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
    Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
    BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.
    Zhang C; Li Z; Xu L; Che X; Wen T; Fan Y; Li C; Wang S; Cheng Y; Wang X; Qu X; Liu Y
    BMC Cancer; 2018 Apr; 18(1):462. PubMed ID: 29690901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
    Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
    Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
    Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological analysis of neoplastic PD-L1-positive EBV
    Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
    Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
    Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
    BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients.
    Wu D; Liu Y; Pang N; Sun M; Wang X; Haridia Y; Zhao F; Qin Y; Fan W; Guo X; Ding J
    Medicine (Baltimore); 2019 Oct; 98(43):e17608. PubMed ID: 31651870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Percentages of PD-1
    Wang Y; Pang N; Wang X; Liu Y; Wang X; Wang L; Sun M; Yasen H; Zhao F; Fan W; Guo X; Ding J
    Hum Vaccin Immunother; 2018 Apr; 14(4):832-838. PubMed ID: 29333980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
    Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
    Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia.
    Jones D; Benjamin RJ; Shahsafaei A; Dorfman DM
    Blood; 2000 Jan; 95(2):627-32. PubMed ID: 10627472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan.
    Iwafuchi H; Nakazawa A; Sekimizu M; Mori T; Osumi T; Iijima-Yamashita Y; Ohki K; Kiyokawa N; Fukano R; Saito AM; Horibe K; Kobayashi R;
    Hum Pathol; 2021 Oct; 116():112-121. PubMed ID: 34363798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.
    Suzuki Y; Kohno K; Matsue K; Sakakibara A; Ishikawa E; Shimada S; Shimada K; Mabuchi S; Takahara T; Kato S; Nakamura S; Satou A
    Cancer Med; 2020 Jul; 9(13):4768-4776. PubMed ID: 32367674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer.
    Chatterjee J; Dai W; Aziz NHA; Teo PY; Wahba J; Phelps DL; Maine CJ; Whilding LM; Dina R; Trevisan G; Flower KJ; George AJT; Ghaem-Maghami S
    Clin Cancer Res; 2017 Jul; 23(13):3453-3460. PubMed ID: 27986748
    [No Abstract]   [Full Text] [Related]  

  • 40. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
    Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
    Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.